Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

M. Brownlee, H. Vlassara, A. Kooney, P. Ulrich, A. Cerami

Research output: Contribution to journalArticle

1007 Citations (Scopus)

Abstract

Age-associated increases in collagen cross-linking and accumulation of advanced glycosylation products are both accelerated by diabetes, suggesting that glucosederived cross-link formation may contribute to the development of chronic diabetic complications as well as certain physical changes of aging. Aminoguanidine, a nucleophilic hydrazine compound, prevented both the formation of fluorescent advanced nonenzymatic glycosylation products and the formation of glucose-derived collagen cross-links in vitro. Aminoguanidine administration to rats was equally effective in preventing diabetes-induced formation of fluorescent advanced nonenzymatic glycosylation products and cross-linking of arterial wall connective tissue protein in vivo. The identification of aminoguanidine as an inhibitor of advanced nonenzymatic glycosylation product formation now makes possible precise experimental definition of the pathogenetic significance of this process and suggests a potential clinical role for aminoguanidine in the future treatment of chronic diabetic complications.

Original languageEnglish (US)
Pages (from-to)1629-1632
Number of pages4
JournalScience
Volume232
Issue number4758
StatePublished - 1986
Externally publishedYes

Fingerprint

Glycosylation
hydrazine
Diabetes Complications
Proteins
Collagen
Connective Tissue
Glucose
pimagedine

ASJC Scopus subject areas

  • General

Cite this

Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., & Cerami, A. (1986). Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science, 232(4758), 1629-1632.

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. / Brownlee, M.; Vlassara, H.; Kooney, A.; Ulrich, P.; Cerami, A.

In: Science, Vol. 232, No. 4758, 1986, p. 1629-1632.

Research output: Contribution to journalArticle

Brownlee, M, Vlassara, H, Kooney, A, Ulrich, P & Cerami, A 1986, 'Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking', Science, vol. 232, no. 4758, pp. 1629-1632.
Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986;232(4758):1629-1632.
Brownlee, M. ; Vlassara, H. ; Kooney, A. ; Ulrich, P. ; Cerami, A. / Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. In: Science. 1986 ; Vol. 232, No. 4758. pp. 1629-1632.
@article{71d28f13ca6d40c5b3c39323521ac553,
title = "Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking",
abstract = "Age-associated increases in collagen cross-linking and accumulation of advanced glycosylation products are both accelerated by diabetes, suggesting that glucosederived cross-link formation may contribute to the development of chronic diabetic complications as well as certain physical changes of aging. Aminoguanidine, a nucleophilic hydrazine compound, prevented both the formation of fluorescent advanced nonenzymatic glycosylation products and the formation of glucose-derived collagen cross-links in vitro. Aminoguanidine administration to rats was equally effective in preventing diabetes-induced formation of fluorescent advanced nonenzymatic glycosylation products and cross-linking of arterial wall connective tissue protein in vivo. The identification of aminoguanidine as an inhibitor of advanced nonenzymatic glycosylation product formation now makes possible precise experimental definition of the pathogenetic significance of this process and suggests a potential clinical role for aminoguanidine in the future treatment of chronic diabetic complications.",
author = "M. Brownlee and H. Vlassara and A. Kooney and P. Ulrich and A. Cerami",
year = "1986",
language = "English (US)",
volume = "232",
pages = "1629--1632",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "4758",

}

TY - JOUR

T1 - Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

AU - Brownlee, M.

AU - Vlassara, H.

AU - Kooney, A.

AU - Ulrich, P.

AU - Cerami, A.

PY - 1986

Y1 - 1986

N2 - Age-associated increases in collagen cross-linking and accumulation of advanced glycosylation products are both accelerated by diabetes, suggesting that glucosederived cross-link formation may contribute to the development of chronic diabetic complications as well as certain physical changes of aging. Aminoguanidine, a nucleophilic hydrazine compound, prevented both the formation of fluorescent advanced nonenzymatic glycosylation products and the formation of glucose-derived collagen cross-links in vitro. Aminoguanidine administration to rats was equally effective in preventing diabetes-induced formation of fluorescent advanced nonenzymatic glycosylation products and cross-linking of arterial wall connective tissue protein in vivo. The identification of aminoguanidine as an inhibitor of advanced nonenzymatic glycosylation product formation now makes possible precise experimental definition of the pathogenetic significance of this process and suggests a potential clinical role for aminoguanidine in the future treatment of chronic diabetic complications.

AB - Age-associated increases in collagen cross-linking and accumulation of advanced glycosylation products are both accelerated by diabetes, suggesting that glucosederived cross-link formation may contribute to the development of chronic diabetic complications as well as certain physical changes of aging. Aminoguanidine, a nucleophilic hydrazine compound, prevented both the formation of fluorescent advanced nonenzymatic glycosylation products and the formation of glucose-derived collagen cross-links in vitro. Aminoguanidine administration to rats was equally effective in preventing diabetes-induced formation of fluorescent advanced nonenzymatic glycosylation products and cross-linking of arterial wall connective tissue protein in vivo. The identification of aminoguanidine as an inhibitor of advanced nonenzymatic glycosylation product formation now makes possible precise experimental definition of the pathogenetic significance of this process and suggests a potential clinical role for aminoguanidine in the future treatment of chronic diabetic complications.

UR - http://www.scopus.com/inward/record.url?scp=0022644227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022644227&partnerID=8YFLogxK

M3 - Article

C2 - 3487117

AN - SCOPUS:0022644227

VL - 232

SP - 1629

EP - 1632

JO - Science

JF - Science

SN - 0036-8075

IS - 4758

ER -